How Sweden's Calliditas Built Up Its US Presence And Development Portfolio
Approval Submission Of Lead Candidate Expected This Quarter
Executive Summary
Interview: delivering on its US business strategy during the COVID-19 pandemic has required a focus on communication, according to Calliditas CEO Renee Aguiar-Lucander.
You may also be interested in...
Travere Positioned To Seek Accelerated Approval In Rare Kidney Disorder
With interim Phase III data showing threefold reduction in proteinuria reduction compared to SOC, Travere plans to seek accelerated US and EU approval of sparsentan in immunoglobulin A nephropathy.
Novartis Challenger To Alexion Advances In Rare Kidney Disease
First-in-class iptacopan could help Novartis expand into kidney disease, and take on Alexion’s blockbuster rare disease franchise.
Deal Watch: RedHill Finds New Partner For Movantik
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.